Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGFR | P43088 | 1/20 | 0.37 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | IDH1 | O75874 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7085518 | 0.99 | PTGFR (0.36) | PTGFRKCNA5KMT2APKMIDH1 | |
| SCHEMBL7081215 | 0.81 | CYP1A2 (0.36) | CYP2C19 | |
| SCHEMBL9423049 | 0.78 | KMT2A (0.43) | PTGFRKMT2A | |
| SCHEMBL7085257 | 0.73 | IDH1 (0.43) | IDH1 | |
| SCHEMBL7104598 | 0.72 | IDH1 (0.35) | KCNA5KMT2AIDH1CYP2C19 | |
| SCHEMBL7085483 | 0.72 | ACLY (0.38) | — | |
| SCHEMBL7088246 | 0.71 | PTGFR (0.45) | PTGFRKCNA5KMT2APKMACHE | |
| SCHEMBL7085267 | 0.71 | ALDH1A1 (0.36) | CYP2C19 | |
| SCHEMBL7607216 | 0.70 | NLRP3 (0.41) | — | |
| SCHEMBL9316222 | 0.69 | CA2 (0.40) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0592439-B1 | AMINOSULFONYL CARBAMATES | WARNER LAMBERT CO (US) | 2003-07-30 | — | — | EP | claimed |
| US-20020183384-A1 | Methods of treating nuclear factor-kappa B mediated diseases and disorders | CORNICELLI JOSEPH ANTHONY (US) | 2002-12-05 | — | — | US | claimed |
| EP-1236468-A1 | Sulfonylaminocarbonyl derivatives for the treatment of nuclear factor-kappa B mediated diseases and disorders | WARNER-LAMBERT COMPANY (US) | 2002-09-04 | — | — | EP | claimed |
| US-5336690-A | Anticholesterol agents | WARNER-LAMBERT COMPANY (US) | 1994-08-09 | — | — | US | claimed |
| EP-0592439-A1 | AMINOSULFONYL CARBAMATES | WARNER-LAMBERT COMPANY (US) | 1994-04-20 | — | — | EP | claimed |
| WO-1992008693-A1 | AMINOSULFONYL CARBAMATES | WARNER-LAMBERT COMPANY (US) | 1992-05-29 | — | — | WO | claimed |
| EP-0592439-B1 | AMINOSULFONYL CARBAMATES | WARNER LAMBERT CO (US) | 2003-07-30 | — | — | EP | disclosed |
| US-20020183384-A1 | Methods of treating nuclear factor-kappa B mediated diseases and disorders | CORNICELLI JOSEPH ANTHONY (US) | 2002-12-05 | — | — | US | disclosed |
| EP-1236468-A1 | Sulfonylaminocarbonyl derivatives for the treatment of nuclear factor-kappa B mediated diseases and disorders | WARNER-LAMBERT COMPANY (US) | 2002-09-04 | — | — | EP | disclosed |
| US-5336690-A | Anticholesterol agents | WARNER-LAMBERT COMPANY (US) | 1994-08-09 | — | — | US | disclosed |
| EP-0592439-A1 | AMINOSULFONYL CARBAMATES | WARNER-LAMBERT COMPANY (US) | 1994-04-20 | — | — | EP | disclosed |
| US-5254715-A | Anticholesterol agents | WARNER-LAMBERT COMPANY (US) | 1993-10-19 | — | — | US | disclosed |
| WO-1992008693-A1 | AMINOSULFONYL CARBAMATES | WARNER-LAMBERT COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183384-A1 | Methods of treating nuclear factor-kappa B mediated diseases and disorders | NFKBIA, IKBKB, RELA | PTGFR 574/4885KCNA5 3914/4885KMT2A 1326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.